How Has Data Misuse Hurt COVID-19 Efforts? How Has Data Misuse Hurt COVID-19 Efforts?

WebMD Chief Medical Officer   John   Whyte   talks with Dr Eric Topol about several COVID-19 studies and the need for responsible research, not'sloppy science'that rushes to promote potential treatments.WebMD
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Public Health & Prevention Expert Interview Source Type: news

Related Links:

We need one million more citizens to volunteer for the COVID-19 vaccine trials. Almost half a million Americans have signed up to be part of the clinical trials, but in order to complete the study, the COVID-19 Prevention Network—formed by the National Institute of Allergy and Infectious Diseases (NIAID) at the U.S. National Institutes of Health—will need more volunteers, and especially more volunteers from diverse backgrounds. The sooner the clinical trials finish accruing patients the sooner we will have results of the vaccine studies. I am a cancer doctor, but like many doctors and researchers have been call...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized COVID-19 Source Type: news
From February to April 2020, drop>20 percent observed for all primary admission diagnoses
Source: The Doctors Lounge - Psychiatry - Category: Psychiatry Tags: Cardiology, Dermatology, Endocrinology, Family Medicine, Geriatrics, Gastroenterology, Gynecology, Infections, AIDS, Internal Medicine, Allergy, Critical Care, Emergency Medicine, Nephrology, Neurology, Nursing, Oncology, Ophthalmology, Orthopedics, ENT, Source Type: news
A Phase 1 trial of an investigational mRNA vaccine to prevent SARS-CoV-2 infection has shown that the vaccine is well-tolerated and generates a strong immune response in older adults. A report published today in the New England Journal of Medicine describes the findings from the study, which was supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured EMA Regulatory Affairs Source Type: news
cbsoptanon.onScriptsReady(function(cmp){cmp.ot.targetingAllowed(function(a){if(a) AnvatoPlayer("p0").init({"mcp":"cbs","width":"100%","height":"100%","video":"4749412","autoplay":false,"titleVisible":false,"accessKey":"EZqvRyKE7qmqDflDPXIw6U7kKZEA0Vx7","accessControl":{"preview":false},"pInstance":"p0","plugins":{"heartbeat":{"account":"cbslocal-global-unified","publisherId":"cbslocal","jobId...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - Category: Consumer Health News Authors: Tags: Boston News Covid-19 Boston, MA Health Healthcare Status Healthwatch Syndicated Local Coronavirus Dr. Mallika Marshall Source Type: news
Publication date: Available online 28 September 2020Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Serdar Kalemci, Aydın Sarıhan, Arife Zeybek
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
Publication date: Available online 28 September 2020Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Mahboobeh Mahdavinia, Christopher Codispoti
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
Baseline IL-6 serum levels>30 pg/ml identify severe COVID-19 patients and should be used to guide the intervention with IL-6R inhibitors, aiming to improve their use in an uncertain and evolving therapeutic scenario.
Source: Journal of Allergy and Clinical Immunology - Category: Allergy & Immunology Authors: Source Type: research
Source: Journal of Asthma and Allergy - Category: Allergy & Immunology Tags: Journal of Asthma and Allergy Source Type: research
The newly described severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) is responsible for a pandemic (Corona virus-induced disease -19, COVID-19). It is now well established that certain comorbidities define high risk patients. They include hypertension, diabetes, and coronary artery disease. In contrast, the context with bronchial asthma is controversial and shows marked regional differences. Since asthma is the most prevalent chronic inflammatory lung disease worldwide and SARS-CoV-2 primarily affects the upper and lower airways leading to marked inflammation, the question arises about the possible clinical an...
Source: Journal of Allergy and Clinical Immunology - Category: Allergy & Immunology Authors: Source Type: research
We thank Zwaveling et  al1 for appreciating our review2 and for their insightful correspondence. They suggest that suppression of angiotensin-converting enzyme-2 (ACE-2) by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) could impair the hydrolysis of des-Arg9-bradykinin and stimulate the bradykinin recepto r type 1 (BKB1) pathway to induce leakage of fluid into the lungs. In support of their hypothesis, they stated that loss of ACE-2 in an animal model aggravated acid-induced pulmonary edema, and these effects are alleviated by administration of recombinant human ACE-2.
Source: Journal of Allergy and Clinical Immunology - Category: Allergy & Immunology Authors: Source Type: research
More News: Allergy | Allergy & Immunology | COVID-19 | International Medicine & Public Health | Science | Study